Celebrity GLP-1 rumors: what the science says vs. TikTok

What's this video probably claiming?

With hashtags pairing Ariana Grande and Selena Gomez alongside GLP-1 drug references, this video almost certainly falls into the now-familiar celebrity body speculation genre. The creator is probably arguing, with varying degrees of confidence, that one or both celebrities have used semaglutide or a similar GLP-1 receptor agonist to change their appearance. The Wicked hashtag ties this to Ariana Grande's recent press cycle, during which her visibly changed physique drew enormous online attention. These videos typically combine paparazzi comparisons, before-and-after stills, and confident declarations about what drug was involved, occasionally naming specific brand products. Fifteen million views means this framing reached a significant audience. The problem is that "celebrity probably used Ozempic" content routinely collapses the distinction between educated speculation and medical fact, and that collapse does real harm to how ordinary viewers understand these medications and their own bodies.

What does the science actually show?

GLP-1 receptor agonists do produce meaningful weight loss in clinical populations. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4 mg weekly produced an average body weight reduction of 14.9 percent over 68 weeks in adults with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide achieved up to 22.5 percent weight reduction at the highest dose over 72 weeks. These are real, clinically meaningful numbers. But they describe population averages across people with obesity or type 2 diabetes, enrolled in randomized controlled trials, with careful dietary monitoring. They do not describe what happens when a person at a healthy weight uses these drugs, which is an entirely different and considerably less studied scenario. Individual variation in response is also substantial. Attributing any specific person's weight change to a specific drug, from a TikTok, is not science.

Where does the social media noise diverge from clinical reality?

Several divergences matter here. First, these videos almost never acknowledge that the celebrities in question have access to world-class trainers, nutritionists, chefs, surgeons, and recovery specialists, making GLP-1 attribution pure guesswork. Second, they typically ignore that semaglutide and tirzepatide carry real side effect profiles. The STEP trials documented nausea in roughly 44 percent of participants, vomiting in 24 percent, and meaningful rates of discontinuation due to gastrointestinal events. Pancreatitis, though rare, is listed as a serious risk. Third, the framing frequently implies these drugs are a cosmetic shortcut accessible to anyone, which misrepresents both their approved indications and the medical supervision they require. Selena Gomez, has lupus and underwent a kidney transplant, meaning she takes immunosuppressants with complex drug interaction profiles. Any speculation about her weight and GLP-1 use requires ignoring that entire medical history, which these videos cheerfully do.

What should you actually know?

If you are watching celebrity body speculation content and walking away with beliefs about what GLP-1 drugs do or who should take them, that is a problem worth correcting. These medications are FDA-approved for specific indications: semaglutide (Wegovy) for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity; tirzepatide (Zepbound) under similar criteria. Use outside those parameters is off-label and warrants genuine medical evaluation, not TikTok inspiration. The Rubino et al. 2021 consensus statement in Obesity Reviews makes the case clearly that obesity pharmacotherapy works best as part of a structured program including behavioral intervention. Long-term data on these drugs in people who are not obese is limited. Celebrity speculation content also consistently omits what happens when people stop: the STEP 4 withdrawal trial (Rubino et al., 2021, NEJM) showed most weight returns within a year after discontinuation without ongoing intervention. That part never goes viral.